MAZE Stock Price, Chart, Stats & News
Maze Therapeutics, Inc. (MAZE) does not currently pay a dividend.
MAZE chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -33.02% |
ROE | -40.70% |
D/E | 0.07x |
Interest coverage ratio | – |
MAZE valuation
P/E | – |
P/S | – |
P/B | 3.68x |
P/CF | -11.66x |
P/FCF | -13.30x |
P/OCF | -11.66x |
PEG | 0.30x |
EV multiple | -11.85x |
About
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.
Similar securities
Based on sector and market capitalization
